Join BIOCYTOGEN at 6th Annual Gulf Coast Vascular Research Symposium

Join BIOCYTOGEN at 6th Annual Gulf Coast Vascular Research Symposium

We are excited to announce our participation as an exhibitor at the 6th Annual Gulf Coast Vascular Research Symposium 2024, one of the world’s premier medical events. Held in Houston from October 29th to 30th, this symposium gathers leading experts and innovators to exchange ideas, gain insights, and inspire new advancements in the field.

What is the Gulf Coast Vascular Research Symposium?

The Gulf Coast Vascular Research Symposium is a prestigious gathering that highlights collaboration and innovation in vascular biology. Hosted at the Texas Medical Center in Houston, GCVS 2024 will bring together over 300 participants, including more than 30 renowned professors and experts, to advance the understanding and treatment of cardiovascular diseases. This symposium provides a unique platform for scientists, educators, clinicians, and trainees to engage in meaningful exchanges, fostering knowledge transfer and innovative partnerships. More than just a conference, GCVS serves as a catalyst for groundbreaking ideas and translational research, bridging laboratory discoveries with clinical applications. As a beacon of hope for the future of healthcare, GCVS shines a light on the complexities of the vascular system and the pioneering research aimed at improving its health.

Event Overview  

Date: October 29th 7:00 am CDT – 30th 4:00 pm CDT

Venue: Houston Methodist Research Institute

Event Schedule

The Gulf Coast Vascular Research Symposium in Houston will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the Gulf Coast Vascular Research Symposium agenda.

About BIOCYTOGEN

Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).

We look forward to seeing you at the 6th Gulf Coast Vascular Research Symposium in Houston!

Share:

Back to top
WordPress Double Opt-in by Forge12